ARSUF (Fagron) Moat Score: 5/10 (As of Jul. 12, 2026)


ARSUF Fagron SA ARSUF
92 GF Score
Price $26.53
GF Value $26.73
! 6 Warning Signs
View Full Analysis

What is Fagron Moat Score?

Fagron ARSUF -1.74% 92 Moat Score is 5 as of Jul. 12, 2026. GuruFocus rates ARSUF with a GF Score™ of 92/100 and a GF Value™ of $26.73. The stock has 6 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Fagron ranks better than 94.67% on this metric.

Fagron has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Fagron has Narrow Moat: Fagron SA has a solid narrow moat due to its strong brand in pharmaceutical compounding and valuable intellectual property. It benefits from economies of scale and a robust distribution network, but lacks significant regulatory barriers or exclusive licenses to elevate it to a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Fagron might have Narrow Moat - Solid narrow moat.

Fagron  (OTCPK:ARSUF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Fagron Moat Score Related Terms

ARSUF vs ZTS, UTHR, VTRS: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Fagron's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fagron Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fagron's Moat Score distribution charts can be found below:

* The bar in red indicates where Fagron's Moat Score falls into.


ARSUF
92GF Score
Fagron SA ARSUF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Fagron (ARSUF) has a Moat Score of 5 as of Jul. 12, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Fagron ranks #55 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is Fagron's Moat Score too high?
Fagron's current Moat Score is 5. Based on the distribution chart, Fagron ranks #55 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Fagron has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does Fagron's Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Fagron ranks #55 out of 1031 companies for Moat Score. This places Fagron in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Fagron's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fagron stock overvalued right now?
Fagron (ARSUF) has a current Moat Score of 5. The stock's GF Value™ is $26.73, compared to a current price of $26.53 — trading 0.7% below its estimated fair value. The current Moat Score is 5. Fagron's overall GF Score™ is 92/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Fagron (ARSUF), the current Moat Score is 5 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fagron (ARSUF) Overvalued in 2026?

Based on GuruFocus' analysis, Fagron stock appears to be undervalued. The current stock price of $26.53 is trading 0.7% below its estimated GF Value™ of $26.73.

Key valuation signals for ARSUF:

  • Moat Score: 5
  • GF Value™: $26.73 vs. price of $26.53 (0.7% below fair value)
  • GF Score™: 92/100 with 6 warning signs

No single metric tells the full story. See the ARSUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fagron Business Description

Address Fascinatio Boulevard 350, Rotterdam, ZH, NLD, 3065 WB
Fagron SA is a Belgium-based multinational pharmaceutical compounding company specializing in pharmaceutical compounding. It operates across the pharmaceutical compounding value chain, developing and manufacturing personalized medicines in collaboration with pharmacists, prescribers, hospitals, and other healthcare providers. The company has three segments: Essentials, Brands, and Compounding Services. The majority of the revenue is derived from the Essentials segment, which provides raw materials, equipment, packaging, and supplies for compounding to pharmacies and healthcare industries across EMEA, Latin America, and North America - Pacific. Geographically, it generates the maximum revenue from Fagron North America - Pacific.
92GF Score

Get the complete analysis for ARSUF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.53
Price
$26.73
GF Value